Aadi Bioscience, Inc. (NASDAQ: AADI) is delighted to welcome Mohammad Hirmand, M.D. to its Board of Directors. Dr. Hirmand brings more than two decades of biotechnology clinical development expertise to the company, most recently serving as executive vice president and chief medical officer for Turning Point Therapeutics, which was acquired by Bristol Myers Squibb (BMS) for a whopping $4.1 billion in August 2022.
With his extensive knowledge and experience, Aadi Bioscience is looking forward to harnessing his invaluable insights to further its mission of developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes.
We are thrilled to have Mohammad join our Board at Aadi, an exciting time as we continue to make progress on FYARRO for unmet clinical needs. Mohammad is a renowned leader in oncology clinical development, bringing a wealth of knowledge to Aadi.
He has a proven track record of success, having been instrumental in the development of Medivation’s Xtandi and Welireg (belzutifan), and leading the development of Turning Point Therapeutics’ clinical pipeline including the tyrosine kinase inhibitor repotrectinib. We are confident that with Mohammad’s guidance, Aadi will continue to grow and expand its clinical offerings.
Caley Castelein, M.D., Aadi Board Chairman, expresses his enthusiasm for Mohammad joining the team: “We look forward to working together and to his contributions as we drive toward continued growth and clinical expansion here at Aadi.”
Dr. Hirmand is a driving force in the cancer research and treatment space, having co-founded Avenzo Therapeutics and serving as its executive vice president and chief medical officer. Prior to this, he was executive vice president and chief medical officer at Turning Point Therapeutics, a publicly traded precision oncology company. During his tenure, he was instrumental in the development of the company until it was acquired by BMS in August 2022.
I am thrilled to join Aadi’s Board of Directors in their groundbreaking mission to unlock the potential of nab-sirolimus to treat mTOR-driven diseases. Aadi’s PRECISION-1 trial, which studies nab-sirolimus in solid tumors with TSC1 and TSC2 inactivating alterations, is a major milestone in targeted oncology. I am eager to collaborate with the remarkable Aadi team and make a meaningful impact on the lives of cancer patients worldwide.
Dr. Hirmand has held a variety of influential positions in the biotechnology industry over the past decade, most recently as chief medical officer of Peloton Therapeutics, until its acquisition by Merck & Co., Inc. in 2019. Prior to this, he was chief medical officer of Medivation, Inc., a publicly traded biotechnology company, from 2007 to 2017, until its acquisition by Pfizer Inc.
He has also held clinical development roles at Nuvelo, Inc., SuperGen, Inc., Tularik, Inc., and Theravance Biopharma, Inc. Dr. Hirmand is a graduate of Harvard Medical School and Cornell University, where he earned a B.A. in Biological Sciences and Economics.
About Aadi Bioscience, Inc.
Aadi is a revolutionary biopharmaceutical company that is changing the landscape of cancer treatment. They have developed precision therapies that target cancers caused by mTOR pathway driver alterations.
Thanks to Aadi’s groundbreaking work, their FDA-approved FYARRO® is now available to treat adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa). This is a game-changer for cancer patients, providing them with a new, effective treatment option.
Aadi has launched PRECISION 1, a revolutionary Phase 2 trial that aims to target malignant solid tumors with TSC1 or TSC2 inactivating alterations. This trial is the first of its kind as it is mTOR inhibitor-naïve and will give new hope to those living with cancer.